Princess Máxima Center

Name

Princess Máxima Center

Legal name

Prinses Máxima Centrum

Website

https://prinsesmaximacentrum.nl

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pediatric Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Children’s Hospitals & Pediatric Health Systems (HLAFAJAG), Medical Oncology (HLAKAFAB)

Keywords

• Pediatric oncology care
• Clinical research hospital
• Childhood cancer treatment
• Clinical trial services
• Survivorship follow-up care

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Healthcare Services: As a national pediatric oncology center, Princess Máxima Center receives government-funded healthcare payments and insurance reimbursements for patient treatment, clinical care, and hospital services.
2. Donations and Foundation: The Princess Máxima Center Foundation accepts donations to support research, care innovations, and programs. Donations are used to advance the mission of achieving 100% cure and better quality of life.
3. Clinical Research Funding: The center conducts pharmaceutical company-sponsored clinical trials and investigator-initiated studies, receiving funding for research coordination, data management, and study execution.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Princess Máxima Center is Europe's largest pediatric oncology research hospital, integrating clinical care, research, and education for children with cancer. It provides direct patient treatment, including specialized therapies such as CAR-T, 131I MIBG, and allogeneic stem cell transplant, coordinates all Dutch pediatric oncology studies, and runs the Trial and Data Center supporting over 100 clinical studies. The center also delivers long-term survivorship care through the LATER-poli and shares expertise via KinderOncoNet and international consortia.

Product overview

Princess Máxima Center is a research hospital for pediatric oncology in the Netherlands, operating as the largest pediatric oncology center in Europe. The organization provides integrated care, research, and education services centered around treating childhood cancer. Key products and services include the Trial and Data Center (providing clinical study support, data management, and data science applications), the Patient Portal, the LATER-poli (long-term follow-up clinic for survivors), and international patient services. The center also operates the Scientific Committee for research oversight, a Knowledge Transfer Office for intellectual property management, and maintains a central biobank for biomaterials and data.

Differentiator

Problem solved

Functional benefit

Brands

• LATER-poli: Specialized follow-up clinic for survivors of childhood cancer addressing late effects of treatment.
• Trial and Data Center (TDC)
• KinderOncoNet

Quantifiable outcome

• 70-80% survival rate for childhood AML with current treatment protocols
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Vereniging Kinderkanker Nederland (formerly VOKK)coreStrategic or Co-development PartnerPatient support organization that has been a co-initiator of the Princess Máxima Center and has contributed significantly to the design and facilities of the center. Provides information, activities, contact opportunities, and advocacy for families of children with cancer. Operates a central location in the center's lobby and support points on each ward.
• SKION (Stichting Kinderoncologie Nederland)coreStrategic or Co-development PartnerTogether with Vereniging Kinderkanker Nederland, forms the Coöperatie Prinses Máxima Centrum voor kinderoncologie, the cooperative structure governing pediatric oncology care in the Netherlands.
• Ronald McDonald HuiskamerminorStrategic or Co-development PartnerTwo Ronald McDonald Huiskamers located within the Princess Máxima Center (on second and third floors), providing family-friendly relaxation spaces with kitchens, living areas, and support for families during their child's treatment.
• NOPHO-DB-SHIP ConsortiumcoreStrategic or Co-development PartnerInternational collaboration of 14 countries in and outside Europe for pediatric hematology and oncology research. Princess Máxima Center participates as sponsor of international studies including the CHIP-AML22 clinical trial.
• ITCC (Innovative Therapies for Children with Cancer)coreStrategic or Co-development PartnerEuropean consortium for pediatric oncology clinical research enabling international collaboration and patient access to innovative therapies.
• Oncode InstitutecoreStrategic or Co-development PartnerPartnership for knowledge transfer and business development. Oncode business developers Saharla Ahmed and Yuva Oz work with the center's KTO to facilitate translation of scientific discoveries into clinical applications.
• Pedal, NANT, SIOPe, PNOC ConsortiacoreStrategic or Co-development PartnerMultiple international pediatric oncology research consortia enabling global collaboration, knowledge sharing, and participation in international clinical studies.
• Villa PardoesminorOthersHoliday accommodation near Efteling that provides free family vacations for families of seriously ill children, including those being treated at Princess Máxima Center.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Texas Children's Hospital: Texas Children's Cancer and Hematology Centers is one of the largest US pediatric oncology programs, with strong research output and clinical trial activity. Comparable to Princess Máxima Center on research integration, advanced therapy offerings, and international patient services.
• St. Jude Children's Research Hospital: St. Jude is the world's largest pediatric cancer research and treatment center, integrating clinical care and research like Princess Máxima Center. It operates an international referral pipeline and a global clinical trial portfolio, making it the most directly comparable peer for scale, mission, and integrated research hospital model.
• SickKids (Hospital for Sick Children): SickKids in Toronto is a leading Canadian pediatric research hospital with significant oncology activity and a charity-funded model similar to Princess Máxima Center. Comparable on integrated research-hospital positioning, biobank infrastructure, and global trial participation.
• Children's Hospital of Philadelphia (CHOP): CHOP's Center for Childhood Cancer Research is one of the largest US pediatric oncology programs, integrating clinical care with translational research. Comparable to Princess Máxima Center on research-hospital model, trial volume, and CAR-T/stem cell transplant offerings.
• Great Ormond Street Hospital for Children (GOSH): GOSH is a major UK pediatric hospital with significant pediatric oncology activity and a charitable funding model similar to Princess Máxima Center. Comparable in national-center positioning, international referrals, and integrated research through the UCL Great Ormond Street Institute of Child Health.
• Dana-Farber/Boston Children's Cancer and Blood Disorders Center: A joint Harvard-affiliated pediatric oncology program combining Dana-Farber's research infrastructure with Boston Children's clinical care. Highly comparable to Princess Máxima Center's research hospital model, with deep clinical trial activity and CAR-T/specialized therapy capabilities.
• Gustave Roussy Institute: Gustave Roussy is a leading European comprehensive cancer center with a dedicated pediatric and adolescent oncology program. Comparable to Princess Máxima Center on European leadership in oncology research, clinical trial sponsorship, and translational integration.
• Seattle Children's Hospital: Seattle Children's is a US pediatric research hospital with a strong oncology program, integrated research through the Ben Towne Center for Childhood Cancer Research, and significant clinical trial activity. Comparable to Princess Máxima Center on research-hospital model and advanced therapy offerings.

Broad incumbents

• Memorial Sloan Kettering Cancer Center: MSK is a leading US adult-and-pediatric oncology center with extensive research capacity. While much broader than Princess Máxima Center, it is comparable on cancer research leadership, clinical trial scale, and translational infrastructure serving as a benchmark.

Regional players

• Charité – Universitätsmedizin Berlin: Charité is a major German university hospital with pediatric oncology activity, broadly comparable in size and academic standing but primarily serving the German market. A regional European peer competing for talent, trials, and consortium leadership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Princess Máxima Center